Cyclophosphamide slowed coronary aneurysm progression in a difficult Kawasaki disease cohort

Children with Kawasaki disease who develop coronary artery aneurysms remain among the most difficult patients in pediatric cardiology. Once aneurysms reach the giant range, the arterial wall has already entered a prolonged inflammatory and remodeling phase, and the risk of thrombosis, stenosis, and later ischemic injury rises sharply. This single-center experience from Shengjing Hospital followed 41 children with Kawasaki disease complicated by coronary artery aneurysms for at least 2 years and compared conventional management alone with a regimen that added cyclophosphamide in selected patients.

The pattern that emerged was clinically specific rather than uniform. Cyclophosphamide appeared most useful in children with more severe coronary involvement, especially right coronary artery disease in the setting of aneurysms measuring at least 4 mm but less than 8 mm with high Z scores. In the largest aneurysms, some partial regression also occurred, but the biological signal was strongest where active vasculitic remodeling still seemed modifiable rather than fixed scarring.

Severe coronary involvement defined the treatment problem

The study enrolled children with at least one coronary artery aneurysm of 4 mm or larger, or a Z score of at least 5. Twenty-one children received conventional treatment and 20 received conventional therapy plus cyclophosphamide, delivered either as a single intravenous dose of 2 mg/kg within a month of disease onset and/or as oral therapy started within 4 months of onset at 1.5 mg/kg/day for 3 months, followed by a 2-month break as one cycle. Mean oral treatment began 2.4 months after disease onset, with an average duration of 4.4 months.

That timing matters because the coronary lesion in Kawasaki disease does not behave like a static scar. It reflects immune-mediated vascular injury, medial destruction, and ongoing repair. Even after fever resolves, the vessel wall can continue to evolve, and aneurysms can either stabilize, regress, or enlarge depending on how much inflammation remains active.

In this cohort, baseline age and sex distribution were similar between groups, which reduces concern that the treatment arm simply started with an easier population. The major clinical question was whether adding cyclophosphamide after the acute febrile phase could still alter coronary outcomes. The answer was mixed across lesion types, but favorable in the subgroup with medium-sized aneurysms and very high Z scores.

RCA regression carried the clearest treatment signal

A striking bedside observation came from two infants with right coronary artery aneurysms of 8.5 mm and 9.1 mm. Both improved over time, with one lesion shrinking from 8.5 mm to 6.3 mm and then to 4.4 mm, and the other decreasing from 9.1 mm to 6.3 mm and then to 4.4 mm on longer follow-up. These are not trivial changes. In a coronary artery that began in the giant range, even partial regression can shift thrombotic risk, long-term surveillance intensity, and the likelihood of later stenosis.

Across the broader cohort, the treatment effect was more modest in the left anterior descending artery and more visible in the right coronary artery. For giant aneurysms involving the right coronary artery, the cyclophosphamide group showed reduction from 7 cases at 1 month to 3 cases at 2 years, while the control group remained at 13 cases. The difference reached statistical significance. In the subgroup with aneurysms of 4 mm to less than 8 mm and Z score at least 10, cyclophosphamide was associated with significant regression as well.

That distribution fits coronary biology. The right coronary artery may, in some patients, remain in a phase of active inflammation and wall remodeling longer than expected, leaving a window in which immunosuppression can blunt progression. Once the aneurysm becomes more fixed or more complex, especially in the left anterior descending territory, the opportunity for meaningful reversal appears narrower.

Two-year imaging suggested a narrower benefit in the right coronary artery

Serial coronary imaging showed the most important change in the subgroup with CAA ≥4 mm and


Reporting by Dr. Aishwarya N., MBBS for Medicine World Foundation, with additional data provided by Frontiers in Immunology.
PRIMARY CLINICAL EVIDENCE & REGISTRY DATA